Independent Data Safety and Monitoring Board (DSMB) recommends continuing study as planned and initiating dosing…
MaaT PharmaJune 28, 2021
L'essai de la thérapie autologue de restauration du microbiote, MaaT011, a atteint ses objectifs principaux…
MaaT PharmaMay 25, 2021
Communiqué de presse Lancement de l’Alliance Promotion Microbiote Le 29 mars 2021 – L’Alliance Promotion…
MaaT PharmaMarch 29, 2021
Study meets primary and key secondary objectives with positive impact and favorable overall safety profile…
MaaT PharmaMarch 17, 2021
Data from 29 patients in the company’s early access program with MaaT013 as a treatment…
MaaT PharmaMarch 11, 2021
Independent Data Safety and Monitoring Board (DSMB) recommends continuing CIMON study and initiating dosing of…
MaaT PharmaDecember 22, 2020
Data showed MaaT013 to be safe and effective in 29 heavily pre-treated and immunocompromised gastrointestinal…
MaaT PharmaDecember 7, 2020
MaaT Pharma Announces Series B Extension and Final Closing with Total of €25 Million ($29.5 Million)
-- New investor Bpifrance leads Series B extension through the PSIM fund it manages on…
MaaT PharmaDecember 1, 2020
Treatment of 29 acute gastrointestinal Graft-versus-Host-Disease patients with full-ecosystem microbiome restoration biotherapeutic MaaT013 reported safe,…
MaaT PharmaNovember 25, 2020
